TB Drug Headed Toward Accelerated Approval: Another Wrinkle for Priority Review Vouchers
This article was originally published in RPM Report
Executive Summary
A positive advisory committee for Janssen’s bedaquiline means the second priority review voucher is probably on its way. And it would be the first for an accelerated approval.
You may also be interested in...
Janssen Plans Tiered Pricing For Sirturo In India; Will Work With Government Agencies For Right Use
The TB treatment will be brought to India with a tiered-pricing mechanism, but Janssen says it will work with partners to ensure appropriate use in a country with the highest population of MDR-TB patients.
Janssen Plans Tiered Pricing For Sirturo In India; Will Work With Government Agencies For Right Use
The TB treatment will be brought to India with a tiered-pricing mechanism, but Janssen says it will work with partners to ensure appropriate use in a country with the highest population of MDR-TB patients.
Market Access Strategies: Pending Approvals, J&J Plans Cautious Steps For Access To Anti-TB Drug Bedaquiline
In an interview, Janssen Chairman Paul Stoffels discusses market access issues related to bedaquiline and J&J’s recent decision to free up patents on its HIV therapy Prezista.